Target- |
MechanismPhotosensitizers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
CLINICAL EFFICACY AND SAFETY OFTAZAROTENE CREAM 0.05% IN THE INITIALAND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI)Last EMA Decision number of Paediatric Investigation Plan: P/0250/2012
Clinical efficacy and safety of R0002 cream in the initial and maintenance therapies of lamellar ichthyosis (LI): a randomised controlled trial
Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-blind, placebo-controlled study
100 Clinical Results associated with Orfagen
0 Patents (Medical) associated with Orfagen
100 Deals associated with Orfagen
100 Translational Medicine associated with Orfagen